JP2004534074A5 - - Google Patents

Download PDF

Info

Publication number
JP2004534074A5
JP2004534074A5 JP2003504977A JP2003504977A JP2004534074A5 JP 2004534074 A5 JP2004534074 A5 JP 2004534074A5 JP 2003504977 A JP2003504977 A JP 2003504977A JP 2003504977 A JP2003504977 A JP 2003504977A JP 2004534074 A5 JP2004534074 A5 JP 2004534074A5
Authority
JP
Japan
Prior art keywords
spironolactone
nanoparticulate
nanosuspension
stabilizer
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003504977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004534074A (ja
JP4536373B2 (ja
Filing date
Publication date
Priority claimed from GBGB0114532.5A external-priority patent/GB0114532D0/en
Application filed filed Critical
Publication of JP2004534074A publication Critical patent/JP2004534074A/ja
Publication of JP2004534074A5 publication Critical patent/JP2004534074A5/ja
Application granted granted Critical
Publication of JP4536373B2 publication Critical patent/JP4536373B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003504977A 2001-06-14 2002-06-14 新規組成物 Expired - Fee Related JP4536373B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0114532.5A GB0114532D0 (en) 2001-06-14 2001-06-14 Novel compositions
PCT/IB2002/003136 WO2002102391A2 (en) 2001-06-14 2002-06-14 Composition comprising nanoparticulate spironolactone

Publications (3)

Publication Number Publication Date
JP2004534074A JP2004534074A (ja) 2004-11-11
JP2004534074A5 true JP2004534074A5 (https=) 2006-01-05
JP4536373B2 JP4536373B2 (ja) 2010-09-01

Family

ID=9916594

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003504977A Expired - Fee Related JP4536373B2 (ja) 2001-06-14 2002-06-14 新規組成物

Country Status (6)

Country Link
US (2) US20040151776A1 (https=)
EP (1) EP1429781A2 (https=)
JP (1) JP4536373B2 (https=)
AU (1) AU2002347094A1 (https=)
GB (1) GB0114532D0 (https=)
WO (1) WO2002102391A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127832D0 (en) * 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
JP2006511525A (ja) * 2002-12-13 2006-04-06 ヤゴテック アーゲー ナノ粒子状スピロノラクトン局所製剤
JP2006089386A (ja) * 2004-09-21 2006-04-06 Nippon Tenganyaku Kenkyusho:Kk ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物
US9023400B2 (en) * 2006-05-24 2015-05-05 Flamel Technologies Prolonged-release multimicroparticulate oral pharmaceutical form
US7897691B2 (en) 2008-05-09 2011-03-01 Gm Global Technology Operations, Inc. Proton exchange membranes for fuel cell applications
JP5185039B2 (ja) * 2008-09-24 2013-04-17 富士フイルム株式会社 光学フィルム、その製造方法、並びにそれを用いた偏光板及び液晶表示装置
WO2017075463A1 (en) * 2015-10-30 2017-05-04 Cmp Development Llc Spironolactone aqueous compositions
US10493083B2 (en) 2015-10-30 2019-12-03 Cmp Development Llc Spironolactone aqueous compositions
MX2023005763A (es) * 2020-11-17 2023-05-29 Arcutis Biotherapeutics Inc Composiciones y metodos para la administracion dermica profunda de farmacos.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011316A (en) * 1975-02-24 1977-03-08 Research Institute For Medicine And Chemistry Inc. Cyclohexa-2,5-diene-1-thiones
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3623376A1 (de) * 1986-07-11 1988-01-21 Behringwerke Ag Pharmazeutische formulierung und verfahren zu deren herstellung
US4837211A (en) * 1987-04-06 1989-06-06 Carolina Medical Products, Inc. Spironolactone composition
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
AU4777896A (en) * 1995-02-10 1996-08-27 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5891469A (en) * 1997-04-02 1999-04-06 Pharmos Corporation Solid Coprecipitates for enhanced bioavailability of lipophilic substances
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
US6180138B1 (en) * 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
DE60019741T2 (de) * 1999-12-08 2006-03-02 Pharmacia Corp., Chicago Nanopartikelzusammensetzungen enthaltend eplerenon
KR20030024849A (ko) * 2000-08-10 2003-03-26 델시스 파머수티컬 코포레이션 소수성 약물의 개선된 고형 약제학적 투여 제제

Similar Documents

Publication Publication Date Title
Wang et al. Advances in antimicrobial organic and inorganic nanocompounds in biomedicine
Kumar et al. Advanced metal and carbon nanostructures for medical, drug delivery and bio-imaging applications
Zhang et al. Supramolecular self-assembly bioinspired synthesis of luminescent gold nanocluster-embedded peptide nanofibers for temperature sensing and cellular imaging
Lu et al. Graphene-based nanomaterials in biosystems
Wang et al. Biocompatible triplex Ag@ SiO2@ mTiO2 core–shell nanoparticles for simultaneous fluorescence‐SERS bimodal imaging and drug delivery
JP2004534074A5 (https=)
JP2005509596A5 (https=)
HK1250646A1 (zh) 纳米粒子免疫偶联物
WO2008027502A3 (en) Carbon nanotube nanocomposites, methods of making carbon nanotube nanocomposites, and devices comprising the nanocomposites
JP2008509068A5 (https=)
JP2005281687A5 (https=)
JP2009538268A5 (https=)
WO2009023304A3 (en) High density nanotube devices
WO2009098404A3 (fr) Procédé de préparation de nanoparticules à base de molécules ou macromolécules amphiphiles fonctionnelles et leur utilisation
Campos et al. Self-assembled inorganic nanomaterials for biomedical applications
Grumezescu Surface chemistry of nanobiomaterials: applications of nanobiomaterials
Singh et al. Surfactant-assisted dispersion of carbon nanotubes: mechanism of stabilization and biocompatibility of the surfactant
Wang et al. Monodispersed graphene quantum dots encapsulated Ag nanoparticles for surface-enhanced Raman scattering
Kwak et al. A review of the ecotoxicological effects of nanowires
WO2009053876A3 (en) Nir emitters excitable in the visible spectral range and their application in biochemical and medical imaging
Singh et al. Hybrid silver nanoparticles: Modes of synthesis and various biomedical applications
Vats et al. Antimicrobial textiles based on nanoparticles and composite, antiviral and antimicrobial coatings based on functionalized nanomaterials
JP2011111444A5 (https=)
Salas-Trevino et al. Carbon nanotubes: An alternative for platinum-based drugs delivery systems
WO2002102391A3 (en) Composition comprising nanoparticulate spironolactone